HHS Shutdown Impacts, New Grant Policies, and Autism Initiatives Amid Organizational Shakeup

The big headline from the Department of Health and Human Services this week is the ongoing impact of the U.S. government shutdown, which started October 1. About 32,000 HHS employees are currently furloughed, pausing or slowing activities at key agencies like the FDA, CDC, CMS, and NIH. These shutdown effects are hitting everything from drug application processing to public health research, and even Medicare claims payments are temporarily on hold. For Medicare providers out there, it’s critical to know that telehealth reimbursement rules have jumped back to pre-pandemic standards—except for behavioral health—so you may need to warn patients that coverage has changed. On the grants front, HHS just rolled out major policy updates. Now, grantees must get prior approval for any budget changes above 10%, compared to the former 25%. There are stricter deadlines for requesting no-cost extensions, and lease improvements now need a formal landlord letter of consent. HHS explicitly reserves the right to terminate awards at its convenience, with no appeal, so organizations relying on HHS funds should check the new Grants Policy Statement now. HRSA confirms all new awards and modifications after October 1 are subject to these rules. Amid these pressures, HHS did not put initiatives on hold altogether. In a recent move to address autism, HHS unveiled its “Autism Action Plan.” The FDA has authorized the use of leucovorin for cerebral folate deficiency linked to autism and expanded Medicaid coverage. The NIH is kicking off new trials on leucovorin’s impact. At the same time, the FDA is updating acetaminophen warning labels and launching a public campaign after ongoing debates around its use in pregnancy and child development. This reflects HHS’s broader commitment to prioritizing research-informed policies, as echoed in recent releases like the Make America Healthy Again Strategy Report, which takes aim at childhood nutrition, vaccine safety, and regulatory reform for drug advertising and approval. HHS is also going through a major organizational shake-up. Five existing agencies are merging into the new Administration for a Healthy America, with significant workforce reductions planned. The CDC is refocusing on infectious diseases, and both the FDA and CDC expect to lose about 20% of their workforce. This reorganization is designed to save taxpayers up to $1.8 billion per year while modernizing how health policy is delivered at the federal level. For American citizens, these changes mean potential delays in health services, stricter research and funding oversight, and sharper transparency in drug and vaccine information. Businesses and healthcare providers have new compliance hurdles for grants and claim processing, while state and local governments must prepare for evolving federal public health priorities and tighter budgets. Internationally, partners are watching how these strategic changes position the U.S. on vaccine science, autism research, and heal This content was created in partnership and with the help of Artificial Intelligence AI.